U. Lalloo (Durban, South Africa), G. Caramori (Marrara Fe, Italy)
Specific immunotherapy efficiency along with the flixothide (fluticosan propionate) therapy for patients suffering from bronchial asthma
O. V. Koretska, L. V. Gribanova, I. A. Rodkina (Dnepropetrovsk, Ukraine)
|  |
Dissociation in effects of fluticasone but not fluticasone/salmeterol on lung function and airway hyperresponsiveness in mild persistent asthma
G. P. Currie, S. Stenback, B. J. Lipworth (Dundee, United Kingdom)
| |
Additive effects of montelukast in salmeterol treated moderate persistent asthmatics
G. P. Currie, D. K. C. Lee, S. J. Fowler, L. M. Cowan, B. J. Lipworth (Dundee, United Kingdom)
| |
Salmeterol/fluticasone propionate in a single inhaler device (SLM/FP) versus theophylline (THEO)+FP in patients with COPD
M. Cazzola, P. Noschese, G. D'Amato, P. Santus, S. Centanni, L. Spicuzza, G. U. Di Maria (Naples, Milan, Catania, Italy)
| |
Effects of histamine and leukotriene antagonism on mannitol and adenosine monophosphate (AMP) challenge
G. P. Currie, K. Haggart, D. K. C. Lee, S. J. Fowler, A. M. Wilson, J. D. Brannan, S. D. Anderson, B. J. Lipworth (Dundee, United Kingdom; Camperdown, Australia)
| |
Initial maintenance therapy with fluticasone propionate/ salmeterol combination product provides superior asthma control versus montelukast or fluticasone propionate alone
P. Dorinsky, C. Crim, S. Yancey, L. Edwards, K. Rickard (Research Triangle Park, United States Of America)
| |
Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD
M. Cazzola, P. Santus, F. Di Marco, B. Boveri, F. Castagna, P. Carlucci, M. G. Matera, S. Centanni (Naples, Milan, Italy)
| |
Airway hyperresponsiveness and treatment effectiveness during a one year study of the combination of salmeterol and fluticasone propionate (FP) compared with FP and salmeterol alone in mild to moderate asthma
B. Lundbäck, E. Rönmark, A. C. Jonsson, L. G. Larsson, F. Pètavy, M. H. James (Stockholm, Lulea, Sweden; Uxbridge, United Kingdom)
| |
Topically applied budesonide and formoterol in combination inhibit rat lung oedema in a synergistic way but counteract the slight systemic effects of each drug alone on body weight gain
M. Lindahl, L. Kallstrom, B. Axelsson, R. Brattsand, A. Miller-Larsson (Lund, Sweden)
| |
Budesonide/formoterol in a single inhaler once or twice daily provides better asthma control than inhaled fluticasone or budesonide alone in patients with moderate persistent asthma
J. P. H. M. Creemers, T. Bantje, A. Eliraz, T. Ekstrom, R. Buhl (Eindhoven, Breda, The Netherlands; Rehovat, Israel; Lund, Sweden; Mainz, Germany)
| |
Budesonide/formoterol in a single inhaler rapidly improves lung function in adult patients with mild or moderate asthma
P. Kuna, U. Lalloo, E. D. Bateman, R. Buhl (Lodz, Poland; Durban, Cape Town, South Africa; Mainz, Germany)
| |
Budesonide/formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroids in patients with mild persistent asthma
J. Ankerst, J. Malolepszy, A. Eliraz (Lund, Sweden; Wroclaw, Poland; Rehovat, Israel)
| |
Prevention of exercise-induced bronchospasm in children with asthma: a comparison of different anti-inflammatory combination therapy
I. V. Smolenov, S. A. Stakhanova, L. M. Ogorodova, J. A. Petrovskaya, N. A. Ivanova, N. G. Mashukova, V. R. Lipina (Volgograd, Tomsk, St-Petersburg, Irkutsk, Ekaterinburg, Russia)
| |
Comparing the 'real-world' effectiveness of daily ICS versus daily leukotriene antagonist with ICS as needed in mild persistent asthma
D. A. Bukstein, A. Luskin, A. Bernstein (Madison, United States Of America)
| |
Tolerance to the protective effect of salmeterol+fluticasone combination (50/250 mcg) on allergen challenge in mild untreated asthmatics
D. Giannini, M. Tonelli, A. Di Franco, E. Bacci, F. L. Dente, M. Taccola, B. Vagaggini, M. Zingoni, R. Testi, P. L. Paggiaro (Pisa, Verona, Italy)
| |
Effect of the addition of montelukast to inhaled fluticasone propionate on immunopathology in bronchial biopsies from mild to moderate asthmatics
S. O' Sullivan, M. McWeeney, M. Akveld, K. S. Berelowitz, C. M. Burke, L. W. Poulter (London, Uxbridge, United Kingdom; Dublin, Ireland)
| |
Adding montelukast versus doubling the budesonide dose in persistent asthma: a subgroup analysis of the COMPACT study
| |
Sequential flexible therapy with formoterol (Foradil®) plus budesonide (Miflonide®) versus a fixed combination of salmeterol and fluticasone (Seretide®) in asthma self-management
| |
Drug utilization in asthmatic children in Russia: a multi-center retrospective study
I. V. Smolenov, N. A. Smirnov, J. J. Zima, N. G. Mashukova (Volgograd, Irkutsk, Russia)
| |